https://trial.medpath.com/news/roche-secures-ce-mark-for-breakthrough-ovarian-cancer-diagnostic-test-rhhby-stock-news 2024-11-18T06:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab 2024-11-18T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-biospace 2024-11-18T06:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-pharma-globenewswire-via-ritzau 2024-11-18T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-gets-positive-ema-opinion-for-biosimilars-targeting-amgen-s-prolia-xgeva 2024-11-18T06:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/child-thriving-after-becoming-world-s-youngest-to-receive-gene-therapy-for-aadc-deficiency 2024-11-18T05:55:38+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-s-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-18T05:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-receives-positive-chmp-opinion-for-fyb203-aflibercept-a-biosimilar-candidate 2024-11-18T05:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-accepts-for-review-the-resubmission-of-sbla-for-dupixent-to-treat-chronic 2024-11-18T05:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/theralase-r-closes-non-brokered-private-placement-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-reports-third-quarter-2024-financial-results-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-setback-gives-bms-commanding-lead-in-schizophrenia-space-biospace 2024-11-18T05:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/two-antibody-therapy-drugs-to-fight-covid-19-get-approval-from-eu-health-body 2024-11-18T04:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-gains-approval-for-skb571-trials-markets-insider 2024-11-18T04:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-markets-insider 2024-11-18T04:48:37+00:00 weekly 0.7 https://trial.medpath.com/news/reconditioned-pacemakers-worked-as-well-as-new-ones-american-heart-association 2024-11-18T04:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-blindsight-implant-receives-fda-breakthrough-designation-usa-herald 2024-11-18T04:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-markets-insider 2024-11-18T03:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/isla-101-phase-2a-b-protect-clinical-trial-progress-update-inn 2024-11-18T03:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-approval-of-bristol-myers-repotrectinib-to-treat-advanced-pharmabiz 2024-11-18T03:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/dental-artificial-intelligence-ai-diagnostic-solution-development-company-ddh-ceo-heo 2024-11-18T02:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/safety-of-simultaneous-vs-sequential-mrna-covid-19-and-inactivated-influenza-vaccines 2024-11-18T02:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/ema-astrazeneca-vaccine-not-recommended-for-people-with-capillary-bleeding-syndrome 2024-11-18T02:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/prostate-cancer-cases-set-to-rise-5-78-by-2028-highlighting-critical-need-for-early-detection 2024-11-18T02:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/european-regulator-endorses-approving-leclaza-combo-therapy-to-treat-nsclc-kbr 2024-11-18T02:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/news-in-brief-inhalerx-neurotech-international-cannabiz 2024-11-18T01:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-medication-nonadherence-and-drug-drug-interaction-testing-on-the-management-of 2024-11-18T01:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/the-global-leader-in-rabies-vaccines-the-serum-free-iterative-rabies-vaccine-of-aim-vaccine 2024-11-18T01:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy 2024-11-18T01:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-gains-approval-for-skb571-trials-tipranks-com 2024-11-18T00:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-tipranks-com 2024-11-18T00:24:01+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-tipranks-com 2024-11-18T00:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-israeli-clinical-trial-is-testing-a-tuberculosis-vaccine-to-prevent-alzheimer-s-opinion 2024-11-18T00:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations-for-gildeuretinol-as-a-treatment-for-stargardt-disease 2024-11-18T00:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/icotrokinra-delivered-an-industry-leading-combination-of-significant-skin-clearance-with-demonstrated-tolerability-in-a-once-daily-pill-in-phase-3-topline-results 2024-11-18T00:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/quell-therapeutics-and-astrazeneca-advance-car-treg-cell-therapy-for-type-1-diabetes-with-10-million-milestone 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/restem-presents-phase-1-data-of-its-ulsc-program-in-globenewswire 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-and-weight-loss-drugs-shown-to-reduce-alcohol-related-hospitalizations-study-finds 2024-11-17T23:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/novel-crispr-cas9-based-promising-in-attr-cardiomyopathy-medpage-today 2024-11-17T23:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/is-ozempic-the-new-miracle-drug-for-patients-with-osteoporosis-related-knee-pain-ausdoc 2024-11-17T23:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/reduced-bleeding-with-abelacimab-could-transform-atrial-fibrillation-treatment 2024-11-17T23:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/two-treatments-that-don-t-work-for-osteoarthritis-medpage-today 2024-11-17T22:34:02+00:00 weekly 0.7 https://trial.medpath.com/news/memphasys-nears-completion-of-key-trial-for-felixtm-system-tipranks-com 2024-11-17T22:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/email-nudges-spur-patients-with-a-history-of-acute-mi-to-get-flu-shots-tctmd-com 2024-11-17T22:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/email-reminders-improved-flu-shot-rates-in-denmark-notably-among-heart-attack-survivors 2024-11-17T21:48:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-checking-boxes-on-prea-requirement-exposure-for-otc-acetaminophen-ibuprofen-ndas 2024-11-17T21:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/emapalumab-may-improve-response-rates-in-mas-treatment-hcplive 2024-11-17T21:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/in-pci-for-mi-spironolactone-does-not-meet-primary-endpoints-but-may-show-benefit-in-hf 2024-11-17T21:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/glorious-neither-exenatide-nor-restrictive-oxygenation-boost-cv-surgery-outcomes 2024-11-17T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/barry-a-borlaug-md-impact-of-tirzepatide-on-cardiorenal-end-organ-damage-in-hfpef 2024-11-17T21:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/spironolactone-a-blood-pressure-medication-may-help-reduce-risk-of-new-heart-failure 2024-11-17T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/genai-breakthrough-new-drug-shows-promising-results-vs-lung-disease-daily-tribune 2024-11-17T20:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-moves-to-eliminate-oral-phenylephrine-from-otc-nasal-decongestants 2024-11-17T20:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/sarilumab-allows-steroid-taper-more-frequently-vs-methotrexate-in-polymyalgia-rheumatica-healio 2024-11-17T20:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-inclisiran-shows-efficacy-improved-adherence-for-reducing-ldl-c-pharmacy-times 2024-11-17T19:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/medical-researchers-to-test-tarantula-venom-for-potential-epilepsy-treatment-abc-news 2024-11-17T19:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-11-17T18:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/early-fda-approval-of-revuforj-boosts-syndax-pharmaceuticals-prospects-and-supports 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/promising-clinical-trial-results-and-future-potential-justify-buy-rating-for-akero-therapeutics 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-promising-hepatitis-b-treatment-data-amid-cautious-optimism-and 2024-11-17T18:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/glorious-exenatide-lacks-preventive-effect-on-organ-injury-in-cardiac-surgery-hcplive 2024-11-17T17:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-presents-new-phase-1-results-for-next-gen-rnai-therapy-nucresiran-in-attr 2024-11-17T15:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/8-health-issues-drugs-like-wegovy-may-treat-besides-weight-loss-study-finds 2024-11-17T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/intensive-blood-pressure-control-benefits-people-with-type-2-diabetes-too 2024-11-17T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/white-button-mushroom-extract-shrinks-tumors-and-delays-their-growth-new-atlas 2024-11-17T15:25:29+00:00 weekly 0.7 https://trial.medpath.com/news/btk-inhibitor-treatment-options-across-the-lymphoma-landscape-cancer-network 2024-11-17T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-markets-insider 2024-11-17T15:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/aim-vaccine-s-serum-free-rabies-vaccine-nears-global-market-entry-markets-insider 2024-11-17T15:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor 2024-11-17T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/news/2d4-a-humanized-monoclonal-antibody-targeting-cd132-is-a-promising-treatment-for-nature 2024-11-17T14:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-s-nucresiran-achieves-96-ttr-reduction-in-phase-1-attr-amyloidosis-trial 2024-11-17T14:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-revolutionizes-heart-failure-treatment-the-pinnacle-gazette 2024-11-17T14:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-biopharma-s-clinical-trial-shows-promise-for-hepatitis-b-treatment-mychesco 2024-11-17T14:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/exenatide-a-glp-1-analog-by-iv-during-cardiac-surgery-did-not-reduce-organ-injury-or-death 2024-11-17T14:23:32+00:00 weekly 0.7 https://trial.medpath.com/news/endometriosis-drug-offers-hope-for-sufferers-who-want-children-daily-mail 2024-11-17T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-too-late-to-buy-viking-therapeutics-stock 2024-11-17T13:57:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocular-nerve-regrowth-following-use-of-diabetes-drug-modern-retina 2024-11-17T13:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/nudge-flu-trial-cardiovascular-focused-messaging-boosts-flu-vaccination-rates-among-heart-attack-survivors 2024-11-17T13:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/the-convergence-of-funding-research-and-collaboration-in-paediatric-brain-cancer-clinical-trials 2024-11-17T13:41:43+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-pr-newswire 2024-11-17T13:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-trial-of-ipilimumab-nivolumab-or-ipilimumab-and-nivolumab-with-or-without-nature 2024-11-17T13:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/historic-redlining-and-contemporary-racism-linked-to-reduced-life-expectancy-aha-study-reveals 2024-11-17T13:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-too-late-to-buy-viking-therapeutics-stock-the-globe-and-mail 2024-11-17T12:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/deep-learning-for-oncologic-treatment-outcomes-and-endpoints-evaluation-from-ct-scans-in 2024-11-17T11:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-tipranks-com 2024-11-17T10:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/sarclisa-recommended-for-eu-approval-by-chmp-to-treat-transplant-ineligible-newly 2024-11-17T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/eu-regulator-urges-caution-over-russia-s-sputnik-v-vaccine-against-covid-19-telegrafi 2024-11-17T09:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-clinical-trial-of-hantaan-and-puumala-virus-dna-vaccines-delivered-by-needle-free-injection 2024-11-17T09:55:13+00:00 weekly 0.7 https://trial.medpath.com/news/mounjaro-appears-to-be-extremely-effective-at-preventing-diabetes-futurism 2024-11-17T09:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-officially-puts-glp-1-meds-on-the-map-for-obesity-related-heart-failure 2024-11-17T09:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/elafibranor-improves-predicted-transplant-free-survival-based-on-globe-uk-pbc-scores 2024-11-17T09:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-17T09:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-to-acquire-clinical-stage-biotechnology-company-biotheus-medical-dialogues 2024-11-17T08:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-watchman-flxtm-left-atrial-appendage-closure-device-demonstrates 2024-11-17T08:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/rivaroxaban-doesn-t-cut-cognitive-decline-stroke-or-tia-in-younger-af-patients 2024-11-17T08:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-reports-promising-phase-1-trial-results-for-nexiguran-ziclumeran-in 2024-11-17T07:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-pharmaceuticals-presentation-by-dr-kevin-garey-at-the-peggy-lillis-foundation 2024-11-17T06:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/5-new-weight-loss-drugs-to-watch-in-the-fight-for-the-next-ozempic-aol-com 2024-11-17T05:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/academic-and-community-partnerships-forge-new-path-in-comprehensive-cancer-care 2024-11-17T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-jaguar-health-reports-revenue-growth-in-q3-2024-investing-com-nigeria 2024-11-17T04:59:12+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-announced-on-the-17th-that-it-received-positive-opinions-on-the-product 2024-11-17T04:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/tce-therapy-demonstrates-quick-responses-for-systemic-lupus-erthematosus-in-early-data 2024-11-17T03:57:33+00:00 weekly 0.7 https://trial.medpath.com/news/summit-trial-proves-tirzepatide-s-benefit-in-hfpef-with-obesity-hcplive 2024-11-17T03:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-providing-feedback-for-pharmacists-improved-care-for-veterans-with-heart-failure 2024-11-17T03:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-says-crispr-therapy-shows-superior-gain-for-cardiomyopathy-patients-stat-news 2024-11-17T03:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-lowered-risk-of-worsening-heart-failure-and-cvd-death-for-obese-adults 2024-11-17T03:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-testing-reshapes-treatment-landscape-in-advanced-pancreatic-cancer-highlighting-promise-of-ras-inhibitors 2024-11-17T03:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-therapy-breakthrough-brings-new-hope-for-treating-deadly-brain 2024-11-17T02:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/there-is-a-clear-link-between-rare-cases-of-blood-clots-and-astrazeneca-vaccine-says 2024-11-17T02:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-quantisnow 2024-11-17T02:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 2024-11-17T00:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/cumberland-pharma-reports-key-clinical-and-business-developments-in-november-2024 2024-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-receives-positive-eu-chmp-opinion-for-pembrolizumab-plus-chemotherapy-as-first 2024-11-16T23:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-tirzepatide-lowers-risk-of-worsening-heart-failure-cvd-death-in-adults-with-obesity 2024-11-16T23:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-application-for-dato-dxd-treatment-in-egfr-mutated-nsclc-cure-today 2024-11-16T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-fsr-receives-globenewswire 2024-11-16T22:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-fsr-receives-confirmation-from-the-department-of 2024-11-16T22:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial-medpage-today 2024-11-16T22:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/vq-101-show-promise-in-interim-phase-1-data-for-gba-parkinson-disease-treatment 2024-11-16T22:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-quantisnow 2024-11-16T22:06:53+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-triplet-boosts-os-over-daratumumab-regimen-in-myeloma 2024-11-16T22:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rems-program-shows-promising-results-for-mavacamten-in-hypertrophic-pharmacy-times 2024-11-16T21:44:28+00:00 weekly 0.7 https://trial.medpath.com/news/fenofibrate-as-an-adjunct-therapy-for-ulcerative-colitis-targeting-in-dddt 2024-11-16T21:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran 2024-11-16T21:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/poster-shows-secukinumab-improves-hs-symptoms-and-psychiatric-comorbidities 2024-11-16T21:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-bjt-778-achieved-100 2024-11-16T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/killing-cancer-cells-with-alpha-particles-could-be-the-next-frontier-in-treatment-cbc-news 2024-11-16T21:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-autoimmune-diseases-in-preclinical-studies 2024-11-16T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-16T20:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza 2024-11-16T20:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-disorders-and-aminotransferase-elevations-cited-as-most-noted-adverse 2024-11-16T20:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-mounjaro-how-dangerous-are-they-the-herald 2024-11-16T20:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-the-preformulated-irrigation-solution-bactisure-r-in-acute-periprosthetic-joint-trials 2024-11-16T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/movano-focuses-on-eviemed-ring-fda-review-and-new-b2b-partnerships 2024-11-16T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/td-cowen-cuts-ascendis-pharma-target-to-153-keeps-buy-rating-investing-com-uk 2024-11-16T18:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/accuracy-of-healthcare-systems-data-for-identifying-cardiovascular-outcomes-after-stroke-due 2024-11-16T18:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/skye-bioscience-surpasses-50-patient-enrollment-in-cbeyond-phase-2-trial-of-pharmabiz 2024-11-16T18:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-drug-only-a-few-eligible-for-treatment-nl-times 2024-11-16T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-gene-editing-therapy-shows-promise-as-cardiac-amyloidosis-treatment-in-early-study 2024-11-16T18:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-triplet-improves-os-in-relapsed-refractory-myeloma 2024-11-16T18:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/expert-discusses-current-trials-in-bladder-cancer-to-watch-for-urology-times 2024-11-16T17:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-crispr-therapy-shows-90-disease-protein-reduction-in-key-clinical-trial 2024-11-16T17:50:09+00:00 weekly 0.7 https://trial.medpath.com/news/usfda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-16T17:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-research-accelerates-with-innovative-treatments-the-pinnacle-gazette 2024-11-16T16:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/biomarin-s-voxzogo-shows-remarkable-height-gains-in-452-child-achondroplasia-study 2024-11-16T16:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-unexplained-changes-in-cholesterol-could-help-identify-adults-at-risk-of-dementia 2024-11-16T16:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/idorsia-launches-aprocitentan-tryvio-in-us-for-treatment-of-hypertension-hcplive 2024-11-16T15:55:12+00:00 weekly 0.7 https://trial.medpath.com/news/life-changing-alzheimer-s-drug-is-approved-for-use-to-reduce-cognitive-decline 2024-11-16T15:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-makes-debut-on-nasdaq-raising-4m-to-advance-skin-cancer-trial-icymi 2024-11-16T15:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-globenewswire 2024-11-16T15:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/ema-human-medicine-committee-recommends-approval-of-sanofi-s-sarclisa-to-treat-pharmabiz 2024-11-16T15:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-a-sea-change-in-frontline-urothelial-carcinoma-treatment-onclive 2024-11-16T15:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-38-drop-in-heart-failure-risk-major-weight-loss-in-trial 2024-11-16T15:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/improving-disease-modification-and-immune-responses-in-myelofibrosis-with-pelabresib 2024-11-16T15:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-16T15:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/summit-tirzepatide-huge-win-for-hfpef-patients-with-obesity-tctmd-com 2024-11-16T15:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-16T15:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-to-launch-new-life-saving-cancer-trials-for-three-major-projects-gloucestershire-live 2024-11-16T14:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-morningstar 2024-11-16T14:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-reports-q3-2024-financial-results-and-clinical-trial-advancements 2024-11-16T14:28:33+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-16T14:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-s-adi-001-shows-breakthrough-car-t-cell-results-in-autoimmune-treatment-study 2024-11-16T14:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-heart-failure-drug-shows-strong-efficacy-across-age-groups-in-phase-3-trial 2024-11-16T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/corin-receives-fda-510-k-clearance-of-icona-femoral-stem-healio 2024-11-16T14:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-one-dose-covid-19-vaccine-gets-green-light-from-eu-regulator 2024-11-16T13:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/greater-institutional-awareness-crucial-for-driving-biotechnology-adoption-csir 2024-11-16T13:59:30+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-16T13:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T13:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-10-onclive 2024-11-16T13:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-progranulin-levels-are-correlated-with-left-ventricular-function-recovery-following 2024-11-16T12:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-first-line-pembrolizumab-plus-chemo-for-unresectable-non-onclive 2024-11-16T12:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-aria-detecting-software-nerivio-gains-expanded-indication-fda-approves 2024-11-16T12:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/tetraspecific-b-nk-cell-better-than-t-cell-engagers-european-biotechnology-magazine 2024-11-16T12:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-providers-critical-for-diversifying-hbv-clinical-trial-recruitment-study-finds 2024-11-16T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/christ-hospital-surgeons-perform-fourth-ever-implant-of-total-artificial-heart-wlwt 2024-11-16T11:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharma-gets-us-fda-approval-for-danziten-tablets-the-first-and-only-nilotinib-with-no 2024-11-16T11:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/promising-non-surgical-treatment-for-early-cataracts-insights-from-a-phase-ii-clinical-trial 2024-11-16T11:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-the-third-dose-of-the-anti-covid-vaccine-telegrafi 2024-11-16T11:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/chicago-northwestern-medicine-study-shows-severe-covid-19-may-shrink-cancer-cells 2024-11-16T11:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/icometrix-s-ai-driven-mri-solution-icobrain-aria-receives-us-fda-clearance-for-safer 2024-11-16T10:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/usmani-projects-a-future-of-car-t-in-community-for-myeloma-and-other-cancers 2024-11-16T10:10:27+00:00 weekly 0.7 https://trial.medpath.com/news/europe-approves-leqembi-for-alzheimer-s-treatment-the-pinnacle-gazette 2024-11-16T09:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ema-announces-that-johnson-johnson-causes-rare-blood-clots-telegrafi 2024-11-16T09:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-in-kmt2a-rearranged-acute-leukemia-targeted-oncology 2024-11-16T09:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-will-present-data-from-the-final-analysis-of-the-globenewswire 2024-11-16T09:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-positive-phase-ii-trial-results-investing-com-uk 2024-11-16T09:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-15-2024 2024-11-16T08:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-approval-of-eisai-biogen-s-lecanemab-to-treat-early 2024-11-16T07:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/merkel-germany-will-buy-russian-vaccines-if-it-receives-ema-approval-telegrafi 2024-11-16T07:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1 2024-11-16T07:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/lack-of-data-on-the-vaccine-ema-postpones-the-approval-of-sputnik-v-telegrafi 2024-11-16T07:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/essential-malaria-drug-artemisinin-shows-signs-of-partial-resistance-in-children-contagion-live 2024-11-16T07:11:16+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-elicits-favorable-efficacy-in-mnpm1-acute-myeloid-leukemia-cancer-network 2024-11-16T07:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-from-sandoz-group 2024-11-16T06:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/a-multicenter-phase-ii-trial-of-triplet-antiemetic-therapy-with-palonosetron-aprepitant-and-nature 2024-11-16T06:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/noam-solomon-bringing-the-human-story-to-ai-pharmaceutical-executive 2024-11-16T05:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/vtp-300-nivolumab-combination-shows-promise-for-functional-hbv-cure-in-phase-2b-trial 2024-11-16T05:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/airway-on-a-chip-could-speed-up-future-drug-and-therapy-development-prweb 2024-11-16T05:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-finds-path-to-leqembi-nod-backs-three-other-new-drugs-biocentury 2024-11-16T04:52:59+00:00 weekly 0.7 https://trial.medpath.com/news/spirovant-sciences-doses-first-subject-in-cystic-fibrosis-gene-therapy-trial 2024-11-16T04:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-biospace 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-expands-clinical-use-of-oncoprism-as-their-ai-enabled-rna-test 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-biospace 2024-11-16T04:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-lag-3-adds-to-keytruda-in-first-line-lung-cancer-citeline-news-insights 2024-11-16T04:19:43+00:00 weekly 0.7 https://trial.medpath.com/news/managing-dual-checkpoint-inhibition-side-effects-in-nsclc-expert-insights-on-treatment-strategies 2024-11-16T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-positive-phase-ii-trial-results-by-investing-com 2024-11-16T03:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical 2024-11-16T02:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-globenewswire 2024-11-16T02:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/life-changing-alzheimer-s-drug-approved-for-use-in-eu-to-reduce-cognitive-decline 2024-11-16T02:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-life-changing-important-alzheimer-s-drug-which-can-drastically-slow-onset-surrey-live 2024-11-16T02:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-markets-insider 2024-11-16T02:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/fully-loaded-secondary-prevention-studies-of-lecanemab-donanemab-alzforum 2024-11-16T01:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-repotrectinib-for-lung-cancer-by-investing-com 2024-11-16T01:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-reports-clinical-efficacy-data-from-canopy-phase-3-trial-of-pemivibart 2024-11-16T00:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study 2024-11-16T00:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-to-present-new-interim-data-from-phase-2-advanced-2-trial-of 2024-11-16T00:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-16T00:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/nih-funding-opportunities-november-2024-university-of-utah-health 2024-11-16T00:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis-2024 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gohibic-for-sars-cov-2-induced-ards-among-eight-new-drugs-to-win-ema-nod 2024-11-15T23:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/pearl-study-compares-first-line-durvalumab-monotherapy-with-chemotherapy-in 2024-11-15T23:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-menin-inhibitor-for-acute-leukemia-medpage-today 2024-11-15T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-markets-data 2024-11-15T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-morningstar 2024-11-15T22:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-s-revuforj-wins-fda-approval-as-first-menin-inhibitor-for-acute-leukemia-sndx 2024-11-15T22:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-strong-financials-strategic-fda-approval-and-growth-prospects-drive 2024-11-15T22:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-15T22:39:49+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-placera 2024-11-15T22:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-cognition-s-fda-approved-alzheimer-s-drug-zunveyl-set-for-2025-launch 2024-11-15T22:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-completes-4m-ipo-for-skin-cancer-treatment-development-mdcx-stock-news 2024-11-15T21:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T21:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemia 2024-11-15T21:50:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revuforj-for-relapsed-refractory-acute-leukemia-subset-cure-today 2024-11-15T21:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-no-birth-defect-risk-from-tetracycline-use-during-first-trimester-of-pregnancy 2024-11-15T21:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-relapsed-refractory-kmt2a-translocated-acute-leukemia 2024-11-15T21:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation-onclive 2024-11-15T21:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/positive-ema-reversal-boosts-biogen-s-leqembi-prospects-despite-challenges 2024-11-15T21:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-aadc-deficiency-treatment-scientist-live 2024-11-15T21:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-wins-on-appeal-chmp-recommends-leqembi-for-alzheimer-s-bioworld 2024-11-15T20:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/filament-health-revenue-slides-94-as-cash-reserves-dwindle-green-market-report 2024-11-15T20:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/european-agency-signals-approval-for-keytruda-for-first-line-mesothelioma-treatment 2024-11-15T20:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/the-joy-of-witnessing-science-transform-a-life-research-horizons 2024-11-15T20:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-ninlotinib-tablets-with-no-mealtime-restrictions-for-cml-oncology-nursing-news 2024-11-15T20:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/outcomes-of-contemporary-therapy-for-cardiogenic-shock-due-to-severe-aortic-stenosis 2024-11-15T20:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/repotrectinib-garners-positive-chmp-opinion-for-ros1-nsclc-and-ntrk-solid-tumors 2024-11-15T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-announces-chmp-opinion-recommending-approval-of-opdivo-plus-yervoy 2024-11-15T20:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-sbla-review-for-dupilumab-in-treatment-of-csu-in-adult-and-pediatric-patients 2024-11-15T19:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/nerivio-ren-wearable-now-fda-cleared-to-treat-migraines-in-children-8-years-and-up 2024-11-15T19:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nilotinib-with-no-mealtime-restrictions-in-ph-positive-cml 2024-11-15T19:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-ag-de000a1ewvy8-ad-hoc-news-de 2024-11-15T19:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/plx-self-sustaining-rise-to-lead-in-renal-rare-disease-zacks-small-cap-research 2024-11-15T19:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-reports-third-quarter-2024-financial-results-yahoo-finance 2024-11-15T19:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/with-phase-iii-myopia-termination-eyenovia-open-to-all-strategic-options-citeline 2024-11-15T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/tamil-nadu-launches-phase-ii-of-uttasathai-uruthi-sei-scheme-to-support-pregnant-women 2024-11-15T19:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-receives-european-commission-approval-for-afqlir-r-aflibercept-further-biospace 2024-11-15T19:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-biospace 2024-11-15T19:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/granite-plus-icis-and-bevacizumab-chemo-shows-improved-pfs-trend-in-mss-mcrc 2024-11-15T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/nmo-drug-looks-good-for-igg4-related-disease-medpage-today 2024-11-15T19:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday-benzinga 2024-11-15T18:47:23+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday 2024-11-15T18:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-reverses-opinion-on-lecanemab-for-alzheimer-disease-but 2024-11-15T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmission-of-supplemental-biologics-license-application-for-dupixent-for 2024-11-15T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-testing-beta-blocker-celiprolol-for-veds-in-phase-3-us-study-ehlers-danlos-news 2024-11-15T18:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/anda-approvals-new-drug-applications-and-505-b-2-applications-third-quarter 2024-11-15T18:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-15T18:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/how-a-biogen-drug-set-the-stage-for-a-new-biotech-targeting-als-biopharma-dive 2024-11-15T18:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-class-of-hemophilia-treatment-coagulation-disorders-jama-network 2024-11-15T18:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-attractive-targeted-sugar-bait-stations-against-malaria-in-western-province-zambia 2024-11-15T18:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-s-car-t-allo-316-demonstrates-ability-to-produce-responses-in-renal-cell 2024-11-15T18:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T18:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/study-launches-of-qxl138am-in-multiple-myeloma-and-solid-tumors-targeted-oncology 2024-11-15T18:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-danziten-for-leukemia-subset-that-does-not-require-fasting-cure-today 2024-11-15T18:04:48+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-receives-european-commission-approval-for-afqlir-r-globenewswire 2024-11-15T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-reviews-sanofi-and-regeneron-s-dupixent-label-expansion-for-urticaria 2024-11-15T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-15T17:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/why-the-ema-said-no-to-kizfizo-and-cinainu 2024-11-15T17:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/two-year-phase-iii-data-confirm-long-term-efficacy-safety-of-bimzelx-in-psoriatic-arthritis 2024-11-15T17:28:35+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-inc-announces-positive-end-of-t-treatment-results-for-tobevibart-and 2024-11-15T17:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-marketing-authorization-to-biosimilar-from-sandoz-group 2024-11-15T17:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T17:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/positive-chmp-opinion-for-formycon-s-aflibercept-biosimilar-fyb203-webdisclosure 2024-11-15T17:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-plus-vrd-earns-chmp-recommendation-for-newly-diagnosed-transplant 2024-11-15T17:12:17+00:00 weekly 0.7 https://trial.medpath.com/news/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-l-amino-acid-decarboxylase-deficiency-gene-therapy-nature 2024-11-15T17:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-chemo-earns-positive-eu-chmp-opinion-in-mesothelioma 2024-11-15T17:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/european-watchdog-partially-approves-new-alzheimer-s-drug-macau-business 2024-11-15T17:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemoradiation-followed-by-immunochemotherapy-and-surgery-may-improve 2024-11-15T17:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/drugs-like-ozempic-may-help-lower-2nd-stroke-heart-attack-risk 2024-11-15T17:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-15T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-four-approvals-and-10-phase-iii-readouts-citeline 2024-11-15T16:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-combination-for-cutaneous-melanoma-the-asco-post 2024-11-15T16:54:52+00:00 weekly 0.7 https://trial.medpath.com/news/ac-immune-s-stock-jumps-after-parkinson-s-therapy-shows-signs-of-benefit 2024-11-15T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/tivic-hits-enrolment-target-for-vagus-nerve-stimulation-trial 2024-11-15T16:51:37+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-nivolumab-ipilimumab-in-msi-h-dmmr-mcrc-onclive 2024-11-15T16:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/an-update-on-therapeutics-for-covid-19-medpage-today 2024-11-15T16:47:31+00:00 weekly 0.7 https://trial.medpath.com/news/research-study-explores-targeted-therapy-for-recurrent-high-grade-glioma 2024-11-15T16:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-application-for-dupilumab-to-treat-chronic-spontaneous-urticaria 2024-11-15T16:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-new-nilotinib-formulation-approval-to-treat-adults-with-chronic-myeloid-leukemia 2024-11-15T16:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-gets-positive-ema-opinion-for-repotrectinib-nyse-bmy-seeking-alpha 2024-11-15T16:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-gene-therapy-kebilidi-to-treat-aadc-deficiency-receives-us-fda-approval 2024-11-15T16:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ptc-therapeutics-kebillidi-for-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-15T16:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/vir-bio-s-hepatitis-b-treatment-shows-46-success-rate-in-key-clinical-trial-stock-titan 2024-11-15T16:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-15T16:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-shares-plummet-70-after-it-drops-lead-program-biospace 2024-11-15T16:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-markets-data 2024-11-15T16:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/promising-hepatitis-b-treatment-data-presented-by-vir-biotechnology-investing-com 2024-11-15T16:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-immunotherapy-aci-7104-056-demonstrates-positive-antibody-responses-in 2024-11-15T16:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-the-nhs-digitrials 2024-11-15T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/barinthus-bio-announces-results-from-ongoing-phase-2b-globenewswire 2024-11-15T16:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-designation-to-elraglusib-for-ewing-sarcoma-oncology-nursing-news 2024-11-15T16:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/in-brief-rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-shares-magazine 2024-11-15T16:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/first-clinical-trial-of-memory-like-natural-killer-cells-in-ovarian-cancer-opens-at-dana-farber 2024-11-15T15:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment 2024-11-15T15:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-rybrevant-r-amivantamab-in-combination-globenewswire 2024-11-15T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-ultrasound-guided-individualized-positive-end-expiratory-pressure-on-the-severity-of 2024-11-15T15:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/how-to-accelerate-glycolysis-and-treat-parkinson-s-disease-drug-discovery-news 2024-11-15T15:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/delandistrogene-moxeparvovec-fails-to-meet-primary-endpoint-in-phase-3-study 2024-11-15T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/application-for-rtw-biotech-opportunities-corxel-s-aficamten-accepted-by-chinese-regulator 2024-11-15T15:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-15T15:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ind-for-as1986ns-a-new-approach-in-prostate-cancer-research 2024-11-15T15:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/foresee-pharmaceuticals-receives-the-second-positive-recommendation-from-dsmb-to 2024-11-15T15:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/drug-combination-boosts-immune-response-in-resistant-pancreatic-cancers 2024-11-15T15:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sets-date-for-resubmitted-dupixent-in-inflammatory-skin-disease-formulary-watch 2024-11-15T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-for 2024-11-15T14:56:53+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-sequencing-and-treatment-options-in-the-tumor-agnostic-setting-cancer-network 2024-11-15T14:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-completes-phase-2b-trial-dosing-awaits-key-december-data-ostx-stock-news 2024-11-15T14:54:09+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T14:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-veliparib-to-temozolomide-in-newly-diagnosed-mgmt-methylated-glioblastoma 2024-11-15T14:45:06+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-strategy-reverses-resistance-to-immunotherapy-in-pancreatic-cancer 2024-11-15T14:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-showcases-early-cancer-detection-test-data-at-aacr-meeting 2024-11-15T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-holding-company-announces-presentation-of-data-at-the-2024-american-college-of 2024-11-15T14:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-s-gloperba-r-showcases-breakthrough-kidney-disease-dosing-data-at-acr-conference 2024-11-15T14:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/cero-therapeutics-secures-fda-clearance-for-novel-aml-treatment-clinical-trial 2024-11-15T14:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/rwanda-steps-up-measures-against-rift-valley-fever-gavi-the-vaccine-alliance 2024-11-15T14:08:51+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-research-promises-shorter-treatment-for-multi-drug-resistant-tb 2024-11-15T13:56:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-decision-on-abeona-s-pz-cel-for-rdeb-now-expected-by-april-29 2024-11-15T13:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-halts-enrollment-in-leukemia-trial-by-investing-com 2024-11-15T13:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-receives-positive-chmp-opinion-for-globenewswire 2024-11-15T13:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/cero-therapeutics-inc-receives-fda-clearance-of-globenewswire 2024-11-15T13:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kebilidi-first-brain-delivered-gene-therapy-for-rare-aadc-disease 2024-11-15T13:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-gets-ema-nod-for-covid-19-treatment-tipranks-com 2024-11-15T13:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/sbrt-is-feasible-for-localized-prostate-cancer-oncology-nursing-news 2024-11-15T13:38:06+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-nasdaq-pdsb-q3-2024-earnings-call-transcript 2024-11-15T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-pushes-nv-387-to-phase-ii-trials-nyse-a-nnvc-proactive-investors 2024-11-15T13:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-reactions-follow-rfk-jr-s-nomination-as-hhs-secretary-raising-public-health-concerns 2024-11-15T13:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/from-the-bench-fall-2024-massachusetts-general-hospital 2024-11-15T13:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/selenium-proteins-breakthrough-in-cancer-research-mirage-news 2024-11-15T13:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/genomadix-inc-enters-into-collaboration-with-mayo-clinic-on-precision-medicine-for-telestroke 2024-11-15T13:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-s-gohibic-gets-ema-panel-nod-for-covid-19-ards-by-investing-com 2024-11-15T12:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-globenewswire 2024-11-15T12:56:02+00:00 weekly 0.7 https://trial.medpath.com/news/leveraging-genetic-variations-for-more-effective-cancer-therapies-news-medical 2024-11-15T12:53:20+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T12:52:23+00:00 weekly 0.7 https://trial.medpath.com/news/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-11-14 2024-11-15T12:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/triglyceride-lowering-therapies-in-hypertriglyceridemia-associated-acute-pancreatitis-in-china 2024-11-15T12:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/shingles-vaccination-shows-dual-benefit-virus-prevention-and-cardiovascular-protection 2024-11-15T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-stock-titan 2024-11-15T12:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-globenewswire 2024-11-15T12:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T12:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-globenewswire 2024-11-15T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-nipocalimab-shows-promise-in-phase-ii-sjogren-s-disease-trial-clinical-trials-arena 2024-11-15T11:59:26+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-tipranks-com 2024-11-15T11:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-antiviral-drug-nv-387-advances-to-phase-ii-trials-amid-funding-needs 2024-11-15T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-advances-nv-387-to-phase-ii-trials-for-multiple-viral-infections 2024-11-15T11:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-review-sanofi-regeneron-s-dupixent-sbla-for-csu 2024-11-15T11:40:58+00:00 weekly 0.7 https://trial.medpath.com/news/more-evidence-that-glp-1-meds-curb-alcohol-abuse 2024-11-15T11:03:32+00:00 weekly 0.7 https://trial.medpath.com/news/chlamydia-vaccine-shows-early-promise-in-mice 2024-11-15T11:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/mymelanoma-study-selected-to-join-new-nhs-digitrials-initiative-oxford-cancer 2024-11-15T10:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/could-weight-loss-drugs-fix-uk-s-unemployment-problem-al-jazeera 2024-11-15T10:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/combination-treatment-for-esophageal-cancer-the-aacr 2024-11-15T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for 2024-11-15T10:22:01+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-positive-outcomes-from-phase-iii-multiple-myeloma-treatment-trial 2024-11-15T10:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-marketscreener 2024-11-15T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-a-new-nhs-digitrials 2024-11-15T10:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-discovery-enables-use-for-muscular-dystrophies-and-large-gene-diseases 2024-11-15T10:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/finally-therapeutic-antibodies-start-to-reduce-tangles-alzforum 2024-11-15T09:52:10+00:00 weekly 0.7 https://trial.medpath.com/news/caamtech-s-psychedelic-functional-unblinding-strategy-gets-regulatory-blessing 2024-11-15T09:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-recommends-sanofi-s-sarclisa-approval-for-multiple-myeloma 2024-11-15T09:23:26+00:00 weekly 0.7 https://trial.medpath.com/news/adding-immunotherapy-to-neoadjuvant-chemoradiation-may-improve-outcomes-in 2024-11-15T09:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/q1-interim-report-july-2024-september-2024-hamlet-biopharma-ab-publ 2024-11-15T08:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:43:36+00:00 weekly 0.7 https://trial.medpath.com/news/the-lasting-impact-of-the-cross-trial-on-gej-cancer-care-targeted-oncology 2024-11-15T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/99-of-mounjaro-zepbound-patients-remained-diabetes-free-even-at-3-years-eli-lilly-s 2024-11-15T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-announces-fda-approval-for-phase-1-trial-of-rhenium-186re-barchart-com 2024-11-15T07:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/a-study-within-a-trial-swat-of-clinical-trial-feasibility-and-barriers-to-recruitment-in-the 2024-11-15T07:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/ema-gives-partial-go-ahead-for-first-alzheimer-s-treatment-in-eu-belganewsagency-eu 2024-11-15T07:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corp-pdsb-q3-2024-earnings-call-highlights-navigating-financial 2024-11-15T07:21:33+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:54:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ptc-s-kebilidi-as-first-gene-therapy-to-treat-aadc-deficiency-rttnews 2024-11-15T06:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-15T06:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/select-mds-1-trial-of-tamibarotene-misses-primary-end-point-in-mds 2024-11-15T06:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/balancing-clinical-data-and-real-world-insights-in-cml-treatment-targeted-oncology 2024-11-15T06:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-wins-eu-approval-for-eylea-biosimilar-to-treat-vision-loss-launch-set-for-2025 2024-11-15T06:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-sbla-accepted-for-fda-review-for-globenewswire 2024-11-15T06:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-glp-1-prescriptions-surge-sevenfold-as-experts-navigate-benefits-and-risks 2024-11-15T05:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating 2024-11-15T05:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-results-from-head-to-head-dreamm-7-phase-iii-trial-of-blenrep-in 2024-11-15T05:29:31+00:00 weekly 0.7 https://trial.medpath.com/news/q3-2024-biomx-inc-earnings-call-yahoo-finance 2024-11-15T05:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-gets-us-fda-approval-for-brain-delivered-gene-therapy-citeline 2024-11-15T05:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-trial-design-key-strategies-for-improving-clinical-research-success 2024-11-15T05:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/elutia-inc-reports-strong-q3-results-prepares-for-major-product-launch-tipranks-com 2024-11-15T05:00:31+00:00 weekly 0.7 https://trial.medpath.com/news/eu-regulator-backs-eisai-biogen-alzheimer-s-drug-the-hindu 2024-11-15T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-l-carnitine-supplementation-on-gastric-emptying-and-bowel-function-in-pediatric 2024-11-15T04:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/munich-to-host-clinical-trials-in-oncology-europe-2024-ai-strategy-and-patient-experience-take-center-stage 2024-11-15T04:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-placera 2024-11-15T04:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-lays-off-45-of-employees-biospace 2024-11-15T04:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-present-updated-os-analysis-of-perla-trial-in-metastatic-nsclc 2024-11-15T04:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/tivic-completes-enrollment-in-nerve-stim-trial-massdevice 2024-11-15T04:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/angiotensin-ii-and-thromboembolism-reading-the-fine-print-critical-care-medicine 2024-11-15T04:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-leaders-share-three-critical-strategies-for-r-d-success-in-drug-development 2024-11-15T04:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-brain-delivered-gene-therapy-approved-for-aadc-deficiency-medpage-today 2024-11-15T03:57:37+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-reports-deeper-losses-as-dmt-clinical-trial-costs-mount 2024-11-15T03:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/delgocitinib-approved-for-adults-with-moderate-to-severe-che-in-switzerland 2024-11-15T03:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/ultrasound-device-garners-fda-de-novo-nod-for-kidney-stone-clearance 2024-11-15T03:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-seeks-fda-approval-for-sleep-enhancing-drug-for-fibromyalgia 2024-11-15T03:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tool-sees-cancer-gene-signatures-in-biopsy-images-news-center-stanford-medicine 2024-11-15T03:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-study-finds-inebilizumab-effective-for-immunoglobulin-g4-related-disease 2024-11-15T02:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-shares-target-cut-rating-held-on-trial-enrollment-issue-investing-com 2024-11-15T02:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-secures-ema-thumbs-up-for-narrower-indication-citeline 2024-11-15T01:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-price-target-lowered-to-4-50-from-7-at-alliance-global-partners 2024-11-15T01:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-pr-newswire 2024-11-15T01:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-15T00:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/merck-is-paying-588m-for-potential-successor-to-cancer-drug-juggernaut-keytruda 2024-11-15T00:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/could-ozempic-help-treat-substance-use-disorder-women-s-health 2024-11-15T00:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revuforj-revumenib-for-the-treatment-of-adult-and-pediatric-patients-with-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T00:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-launches-search-for-150000-volunteers-to-help-transform-cancer-treatment 2024-11-15T00:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-study-of-bat4406f-shows-promise-for-nmosd-treatment 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/va-launches-progress-study-to-enhance-prostate-cancer-screening-with-genetic-testing 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-zolbetuximab-for-cldn18-2-her2-negative-gastric-and-gej 2024-11-14T23:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-bimzelx-r-bimekizumab-bkzx-data-at-acr-convergence-2024-highlights-ucb 2024-11-14T23:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nilotinib-tablets-without-mealtime-restrictions-for-cml-onclive 2024-11-14T22:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-danziten-for-chronic-myeloid-leukemia-without-mealtime-restrictions 2024-11-14T22:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/vivolta-partners-with-neurochase-to-manufacture-electrospun-microcatheters-for-delivery-of 2024-11-14T22:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-wins-first-fda-approval-for-a-gene-therapy-dosed-directly-into-the-brain 2024-11-14T22:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/larger-study-supports-safety-of-tetracyclines-during-early-pregnancy-medpage-today 2024-11-14T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/drug-being-tested-to-address-side-effects-of-cancer-treatment-nebraska-medicine 2024-11-14T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/osteal-therapeutics-announces-positive-12-month-results-from-the-apex-clinical-trial 2024-11-14T22:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-demonstrates-significant-benefits-for-patients-with-pre-diabetes-obesity-over 2024-11-14T22:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/world-diabetes-day-2024-looking-back-at-progress-for-cell-and-gene-therapy-cgtlive-r 2024-11-14T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/nilotinib-tablets-approved-by-fda-for-ph-cml-in-chronic-phase-cancer-network 2024-11-14T21:59:42+00:00 weekly 0.7 https://trial.medpath.com/news/panbela-provides-business-update-and-reports-q3-2024-financial-results 2024-11-14T21:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-reports-third-quarter-2024-financial-results-and-business-updates-morningstar 2024-11-14T21:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-to-present-new-prespecified-subgroup-analyses-from-investigational-phase-iii 2024-11-14T21:55:40+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-medtech-advances-into-surgical-robotics-with-ottava-clinical-trials-zenopa 2024-11-14T21:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/2024-updates-in-gi-cancer-feature-flot-combinations-restricted-fda-approvals-by-pd 2024-11-14T21:49:58+00:00 weekly 0.7 https://trial.medpath.com/news/osteal-therapeutics-announces-positive-12-month-results-globenewswire 2024-11-14T21:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-gene-therapy-for-rare-neurometabolic-disorder-healio 2024-11-14T21:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-first-patient-dosed-in-iggenix-accelerate-peanut-phase-1-clinical-trial-healio 2024-11-14T21:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-wins-over-european-regulators-on-alzheimer-s-drug-leqembi-biopharma-dive 2024-11-14T21:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-reports-third-quarter-2024-financial-results-and-business-updates-stock-titan 2024-11-14T21:39:35+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/genelux-corporation-reports-third-quarter-2024-financial-globenewswire 2024-11-14T21:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/ticker-biogen-alzheimer-s-drug-gets-second-look-in-eu-ford-takes-165m-hit-on-slow-recall 2024-11-14T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-clinical-trial-evaluating 2024-11-14T21:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024-stock-titan 2024-11-14T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-unveils-breakthrough-cancer-drug-platform-reports-positive-phase-2-trial-results 2024-11-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/dare-bioscience-reports-third-quarter-2024-financial-results-and-provides-company-update 2024-11-14T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024 2024-11-14T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/mirdametinib-yields-significant-responses-and-hrqol-improvements-in-nf1-pn 2024-11-14T21:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-sought-for-dato-dxd-in-egfr-mutated-nsclc-targeted-oncology 2024-11-14T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of 2024-11-14T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy-yahoo-finance 2024-11-14T20:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-14T20:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-fda-approves-car-t-therapy-for-r-r-b-all-regmednet 2024-11-14T20:41:32+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-tirumotecan-shows-antitumor-activity-in-previously-treated-endometrial-onclive 2024-11-14T20:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-prevents-type-2-diabetes-in-99-of-prediabetic-patients-for-3-years 2024-11-14T20:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-3-trial-of-amezalpat-in-advanced-liver-cancer-receives-study-may-proceed-letter 2024-11-14T20:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-committee-outlines-informed-consent-best-practices-jd-supra 2024-11-14T19:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-breakthrough-revolutionizing-postpartum-depression-walb 2024-11-14T19:58:27+00:00 weekly 0.7 https://trial.medpath.com/news/recommendations-for-detection-assessment-and-management-of-suspected-drug-induced 2024-11-14T19:50:31+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-secures-ema-thumbs-up-for-narrower-indication 2024-11-14T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/european-watchdog-partially-approves-new-alzheimer-s-drug-barron-s 2024-11-14T19:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-speaks-out-about-bone-density-concerns-with-obesity-drug-clinical-trials-arena 2024-11-14T19:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-r-acute 2024-11-14T19:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/european-committee-takes-a-second-look-at-alzheimer-s-drug-and-now-says-it-should-be-approved 2024-11-14T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-ceo-dr-raza-bokhari-on-4m-nasdaq-ipo-phase-2-trial 2024-11-14T19:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with 2024-11-14T19:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-chemotherapy-enhances-responses-is-well-tolerated-in-hodgkin-lymphoma 2024-11-14T19:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/everything-you-need-to-know-about-nice-s-decisions-on-game-changing-alzheimer-s-drugs 2024-11-14T19:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kebilidi-as-first-gene-therapy-to-treat-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-14T19:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/european-watchdog-partially-approves-new-alzheimer-s-drug-ndtv 2024-11-14T18:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-s-alzheimer-s-drug-lecanemab-wins-key-eu-panel-backing-after-appeal 2024-11-14T18:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/ema-rethinks-stance-committee-now-recommends-leqembi-for-alzheimer-s-disease 2024-11-14T18:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development 2024-11-14T18:37:36+00:00 weekly 0.7 https://trial.medpath.com/news/eu-reverses-course-approval-for-breakthrough-alzheimer-s-drug-leqembi-recommended 2024-11-14T18:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-and-avd-the-new-standard-in-hodgkin-lymphoma-national-cancer-institute 2024-11-14T18:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-posts-second-quarter-loss-widens-as-clinical-trials-advance-green-market-report 2024-11-14T17:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-provides-clinical-programs-update-marketscreener 2024-11-14T17:44:09+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-markets-data 2024-11-14T17:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/kebilidi-aadc-deficiency-gene-therapy-now-approved-by-fda 2024-11-14T17:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-sarclisa-recommended-for-eu-approval-marketscreener 2024-11-14T17:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T17:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-sarclisa-recommended-for-eu-approval-morningstar 2024-11-14T17:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/wet-amd-therapeutics-technologies-raising-the-ceiling-for-functional-visual-outcomes 2024-11-14T17:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/mounjaro-lowers-type-2-diabetes-risk-in-phase-3-trial-study-becker-s-hospital-review 2024-11-14T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sarclisa-recommended-for-eu-approval-by-the-chmp-to-treat-transplant 2024-11-14T17:18:18+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-markets-data 2024-11-14T17:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/eftilagimod-alpha-plus-pembrolizumab-chemo-generates-improved-survival-trends-in 2024-11-14T17:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-polypid-reports-on-d-plex100-trial-and-financials-investing-com-uk 2024-11-14T17:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-stock-titan 2024-11-14T17:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/eu-backs-eisai-alzheimer-s-drug-in-reversal-of-earlier-rejection-bnn-bloomberg 2024-11-14T17:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/eu-backs-leqembi-a-breakthrough-in-alzheimer-s-treatment-health-devdiscourse 2024-11-14T17:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-prevention-trial-receives-74-5-million-nih-grant 2024-11-14T17:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-pr-newswire 2024-11-14T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-icobrain-aria-first-ai-tool-for-safer-aria-detection-in-alzheimer-treatment 2024-11-14T17:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial 2024-11-14T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/tau-modification-drugs-take-a-hit-with-negative-trial-alzforum 2024-11-14T16:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-weakness-in-drug-resistant-tuberculosis-pathogens-news-medical 2024-11-14T16:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-wins-us-approval-of-gene-therapy-for-fatal-enzyme-disorder-biopharma-dive 2024-11-14T16:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/the-breast-cancer-after-care-better-care-programme-to-improve-breast-cancer-follow-up 2024-11-14T16:47:14+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sarclisa-recommended-for-eu-approval-by-the-globenewswire 2024-11-14T16:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/microbion-reports-topline-data-from-phase-ii-study-of-dfi-therapy-clinical-trials-arena 2024-11-14T16:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-formation-and-openai-design-ai-tool-to-slash-clinical-trial-timelines-oodaloop 2024-11-14T16:35:30+00:00 weekly 0.7 https://trial.medpath.com/news/are-glp-1-drugs-really-for-everybody-nature-medicine 2024-11-14T16:29:22+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu 2024-11-14T16:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-breakthrough-device-decisions-rebound-after-recent-declines-medtech-dive 2024-11-14T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial-clinical-trials-arena 2024-11-14T16:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-nets-aadc-gene-therapy-approval-first-brain-delivered-gene-therapy-in-u-s 2024-11-14T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-morningstar 2024-11-14T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-of-biospace 2024-11-14T15:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/new-weight-loss-drug-cuts-appetite-without-causing-muscle-loss-study-finds 2024-11-14T15:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/reach-completes-phase-ii-of-future-force-energy-campaign-with-u-s-air-force-morningstar 2024-11-14T15:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-cancer-biomarkers-promise-improved-survival-inside-precision-medicine 2024-11-14T15:38:31+00:00 weekly 0.7 https://trial.medpath.com/news/nrxbf-gains-another-governmental-designation-zacks-small-cap-research 2024-11-14T15:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-gene-therapy-to-treat-aadc-deficiency 2024-11-14T15:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-reports-trial-results-of-tirzepatide-for-treating-obesity-and-pre-diabetes 2024-11-14T15:31:33+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-breast-imaging-reduces-need-for-axillary-lymph-node-dissection-in-breast-cancer 2024-11-14T15:30:23+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-to-present-12-month-phase-2-data-for-cyb003-in-major-depressive-disorder-on 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-egfr-inhibition-marks-transformative-era-in-lung-cancer-treatment 2024-11-14T15:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/in-case-you-missed-it-roundup-from-esmo-congress-2024-the-asco-post 2024-11-14T15:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-gene-therapy-for-debilitating-enzyme-deficiency 2024-11-14T15:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-presents-positive-phase-ii-data-for-novel-globenewswire 2024-11-14T15:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-demonstrates-significant-clinical-improvement-in-disease-activity-and-igg 2024-11-14T15:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-gains-buy-rating-following-fda-approval-of-groundbreaking-gene 2024-11-14T15:13:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-clinical-trial-of-ata-200-gene-therapy-for-lgmd-children 2024-11-14T15:10:55+00:00 weekly 0.7 https://trial.medpath.com/news/review-approving-using-jak-inhibitors-for-better-alopecia-areata-outcomes 2024-11-14T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-14T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-combination-shows-promise-in-metastatic-kidney-cancer-medpage-today 2024-11-14T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-positive-results-for-potential-treatment-to-combat-a-challenging-rare-disease 2024-11-14T15:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-drug-rejections-have-one-fatal-flaw-realclearhealth 2024-11-14T15:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-outlines-new-strategy-amid-tecelra-launch 2024-11-14T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-eladocagene-exuparvovec-tneq-for-treatment-of-aadc-deficiency 2024-11-14T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-side-effects-no-worse-in-clinical-use-than-they-were-in-trial-alzforum 2024-11-14T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-single-crispr-treatment-could-replace-a-lifetime-of-daily-treatment-in-hereditary-angioedema 2024-11-14T14:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/widely-integrated-services-in-home-wish-for-homebound-older-adults-a-study-protocol-for 2024-11-14T14:36:57+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-ii-top-line-data-highlights-omadacycline-s-potential-in-the-ntm-market 2024-11-14T14:36:15+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-globenewswire 2024-11-14T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/candel-therapeutics-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy 2024-11-14T14:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/actinium-pharmaceuticals-reports-data-from-phase-iii-trial-of-aml-treatment-msn 2024-11-14T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-looks-at-why-cancer-treatments-cause-heart-damage-uc-san-francisco 2024-11-14T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/malaria-developing-resistance-to-drug-that-saves-children-s-lives 2024-11-14T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corp-reports-q3-2024-gaap-eps-of-0-29-missi-gurufocus 2024-11-14T13:55:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-car-t-therapy-for-adults-with-acute-leukemia-cancer-health 2024-11-14T13:54:26+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-reports-third-quarter-2024-results-and-other-exciting-events 2024-11-14T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/medistim-launches-clinical-study-on-ttfm-and-hfus-in-vascular-surgery-finansavisen 2024-11-14T13:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/missing-outcome-data-in-randomised-clinical-trials-of-psychological-interventions-bmc-psychiatry 2024-11-14T13:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-therapeutics-announces-third-quarter-2024-financial-results-and-provides 2024-11-14T13:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-defends-obesity-drug-amid-bone-concerns-stat-news 2024-11-14T13:38:24+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-raises-7-5m-in-public-offering-for-clinical-trials-cldi-stock-news 2024-11-14T13:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-pr-newswire 2024-11-14T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-yahoo-finance 2024-11-14T13:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-biotech-provides-clinical-programs-update-and-reports-third-quarter 2024-11-14T13:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-biotech-accelerates-phase-3-aml-trial-data-timeline-to-h2-2025-mbrx-stock-news 2024-11-14T13:19:18+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer 2024-11-14T13:18:06+00:00 weekly 0.7 https://trial.medpath.com/news/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T13:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-gets-fda-nod-for-kebilidi-to-treat-aadc-deficiency 2024-11-14T13:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-yahoo-finance 2024-11-14T13:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-age-indication-for-nerivio-migraine-device-in-pediatric-patients 2024-11-14T13:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/candel-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T13:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-s-denifanstat-earns-fda-breakthrough-status-reports-170m-cash-position 2024-11-14T13:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-wins-first-fda-nod-for-direct-to-brain-gene-therapy-targets-ultrarare-disease 2024-11-14T12:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-pr-newswire 2024-11-14T12:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-morningstar 2024-11-14T12:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-stock-titan 2024-11-14T12:40:01+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-abbisko-share-positive-phase-3-results-for-pimicotinib-in-rare-tumour-type 2024-11-14T12:35:18+00:00 weekly 0.7 https://trial.medpath.com/news/intelligent-gears-up-for-fda-approval-of-fingerprint-drug-detection-device-yahoo-finance 2024-11-14T12:21:35+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-expands-clinical-trials-to-40-sites-reports-183m-cash-position-caba-stock-news 2024-11-14T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/appili-therapeutics-reports-fda-approved-drug-launch-advances-vaccine-pipeline-in-q2 2024-11-14T12:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-abeona-therapeutics-bla-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-11-14T12:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/protalix-biotherapeutics-reports-third-quarter-2024-financial-and-business-results 2024-11-14T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/khondrion-receives-fda-clearance-of-ind-application-for-globenewswire 2024-11-14T12:14:42+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-therapeutics-announces-third-quarter-2024-globenewswire 2024-11-14T12:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-conclusive-phase-iii-trial-on-tirzepatide-marketscreener 2024-11-14T12:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-the-first-ai-driven-mri-solution-for-safer-alzheimer-s-treatment-biospace 2024-11-14T12:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/aha-study-reveals-major-gap-in-sexual-health-guidance-for-cardiovascular-patients 2024-11-14T11:59:07+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-announces-fda-breakthrough-device-designation-for-axesstm-and-first-patient 2024-11-14T11:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/mild-alzheimer-s-patients-won-t-save-cassava-sciences-drug-stat-news 2024-11-14T11:33:14+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-announces-publication-of-results-globenewswire 2024-11-14T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-eyes-phase-3-registrational-study-for-gene-therapy-ngn-401-following 2024-11-14T11:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapeutic-vaccine-gives-hope-against-an-aggressive-breast-cancer 2024-11-14T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-s-drug-molecule-cbl-514-to-treat-dercum-s-disease-receives-ema-orphan-drug-designation 2024-11-14T10:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-fights-lethal-childhood-brain-cancer-in-stanford-medicine-trial 2024-11-14T10:02:43+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-breakthroughs-bring-new-hope-for-treating-solid-tumors-news-medical 2024-11-14T09:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/leaf-trauma-an-intersectoral-prospective-multicenter-study-assessing-quality-of-life-and-plos 2024-11-14T08:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/syros-slammed-by-phase-iii-data-with-tamibarotene-in-mds-bioworld 2024-11-14T08:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/around-the-helix-cell-and-gene-therapy-company-updates-november-13-2024 2024-11-14T08:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial 2024-11-14T08:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/implantica-submits-fda-pma-application-clinical-module-2-for-refluxstoptm-for-u-s-market-approval 2024-11-14T07:51:33+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-landscape-analysis-current-therapeutic-approaches-for-grade-3-well-differentiated-neuroendocrine-tumors 2024-11-14T07:40:08+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-14T07:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/information-about-the-annual-report-2023-2024-diamyd-medical-ab-cision-news 2024-11-14T07:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/japan-adopts-early-approval-scheme-for-infectious-disease-drugs-citeline 2024-11-14T07:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/interim-report-for-the-period-july-september-2024-bioarctic-cision-news 2024-11-14T07:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-health-inc-jagx-q3-2024-earnings-call-highlights-reven-gurufocus 2024-11-14T07:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-gets-fda-okay-for-first-brain-delivered-gene-therapy-pharmaphorum 2024-11-14T07:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-nears-second-approval-for-tcr-t-therapy-european-biotechnology 2024-11-14T07:24:58+00:00 weekly 0.7 https://trial.medpath.com/news/bergenbio-asa-fra-7bg0-q3-2024-earnings-call-highlights-strat-gurufocus 2024-11-14T07:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-gsk 2024-11-14T07:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/bergenbio-asa-fra-7bg0-q3-2024-earnings-call-highlights-yahoo-finance 2024-11-14T07:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/europe-can-learn-from-israel-s-uniquely-positioned-healthtech-ecosystem 2024-11-14T06:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-receives-buy-rating-from-tyler-van-buren-due-to-clinical-progress-and 2024-11-14T06:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/insights-from-the-spyral-htn-off-and-htn-on-med-trials-hypertension-research-nature 2024-11-14T05:57:47+00:00 weekly 0.7 https://trial.medpath.com/news/twice-yearly-lenacapavir-injections-significantly-reduce-hiv-risk-purpose-2-trial-shows 2024-11-14T05:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-reports-financial-results-for-the-first-nine-months-of-2024-yahoo-finance 2024-11-14T05:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-14T05:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-reports-q3-results-amid-shield-ii-trial-progress-tipranks-com 2024-11-14T04:07:38+00:00 weekly 0.7 https://trial.medpath.com/news/pharvaris-reports-third-quarter-2024-financial-results-and-highlights-recent-business-updates 2024-11-14T03:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-sars-cov-2-infection-on-respiratory-and-gut-microbiome-stability-nature 2024-11-14T02:48:10+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-finance-news-network 2024-11-14T02:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/perceptive-eclinical-unveils-clinphone-5-next-generation-clinical-trial-management-platform 2024-11-14T01:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/the-il-1b-inhibitor-canakinumab-in-previously-treated-lower-risk-myelodysplastic-syndromes 2024-11-14T01:39:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-danziten-nilotinib-tablets-the-first-and-only-nilotinib-with-no-mealtime-restrictions 2024-11-14T01:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/vaccine-shows-promise-against-aggressive-breast-cancer-washu-medicine 2024-11-14T01:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/innovationrx-positive-clinical-trial-results-for-generative-ai-designed-drug-forbes 2024-11-14T00:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-finance-news-network 2024-11-14T00:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-shows-98-7-diabetes-prevention-at-3-years-drug-discovery-and-development 2024-11-14T00:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapeutic-approach-for-severe-covid-19-faster-recovery-and-reduction-in-mortality 2024-11-14T00:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-announces-positive-results-from-phase-3-maneuver-study-of-pimicotinib-to-treat 2024-11-14T00:29:43+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-announces-publication-of-results-from-phase-3-study-of-morningstar 2024-11-14T00:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of-behcet-s-disease 2024-11-14T00:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-submit-bla-to-fda-for-lung-cancer-treatment 2024-11-14T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-for-alzheimer-s-granted-breakthrough-device-status-by-fda 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spero-therapeutics-reports-third-quarter-2024-financial-results-and-business-update 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-developments-in-biosimilars-and-pharmaceuticals-in-2024 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-says-drug-combo-contains-lung-cancer-from-spreading-for-longer 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gri-bio-advances-phase-2a-trial-of-gri-0621-for-idiopathic-pulmonary-fibrosis-with-promising-interim-safety-data 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/traws-pharma-provides-business-update-and-reports-q3 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pila-pharma-announces-selection-of-clinical-trial-site-and-decision-to 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-leo-pharma-s-filing-of-delgocitinib-cream-new 2024-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/piecing-together-the-proper-btk-usage-in-cll-onclive 2024-11-13T23:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-why-tb-drug-fights-resistant-strains-mirage-news 2024-11-13T23:40:43+00:00 weekly 0.7 https://trial.medpath.com/news/nlrp3-protein-inhibitors-clinical-trial-pipeline-appears-globenewswire 2024-11-13T23:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-ptc-therapeutics-gene-therapy-for-aadc-deficiency 2024-11-13T23:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ptc-therapeutics-gene-therapy-upstaza-for-aadc-deficiency-cgtlive-r 2024-11-13T23:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/clearpoint-neuro-makes-history-with-first-fda-approved-brain-gene-therapy-device 2024-11-13T23:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-13T23:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-announces-financial-results-for-the-fiscal-second-quarter-ended 2024-11-13T22:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/75-key-companies-charting-new-frontiers-in-multiple-sclerosis-therapeutic-space-delveinsight 2024-11-13T22:48:31+00:00 weekly 0.7 https://trial.medpath.com/news/rbc-s-insights-on-biotech-stocks-top-investor-questions-answered 2024-11-13T22:46:34+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-s-pemvidutide-a-promising-obesity-treatment-with-strategic-phase-iii-development 2024-11-13T22:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-full-approval-of-liver-disease-drug-becker-s-hospital-review 2024-11-13T22:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/smile-stereotactic-multiple-fraction-radiotherapy-for-non-spine-bone-metastases-trials 2024-11-13T22:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/no-rara-syros-trouble-mds-phase-iii-sinks-tamibarotene-bioworld 2024-11-13T22:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/a-study-of-the-efficacy-and-safety-of-kus121-in-participants-with-acute-non-arteritic-central 2024-11-13T22:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/metsera-raises-215m-to-accelerate-obesity-drug-plans-biopharma-dive 2024-11-13T22:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/all-in-the-blood-new-way-to-detect-drug-resistance-in-ovarian-cancer-patients-wehi 2024-11-13T22:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/vicarious-surgical-says-first-surgical-robot-trials-remain-on-track-massdevice 2024-11-13T22:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/cmc-pharma-extends-shelf-life-of-medical-countermeasure-receives-fda-approval 2024-11-13T21:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-reports-q3-eps-1-39-consensus-73c-tipranks-com 2024-11-13T21:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/woods-cho-awarded-76m-nih-grant-to-conduct-clinical-trials-for-youth-at-risk-for-schizophrenia 2024-11-13T21:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/nurexone-s-exopten-secures-ema-orphan-drug-status-for-spinal-cord-injury-treatment 2024-11-13T21:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/diamedica-updates-remedy2-trial-timeline-reports-50-2m-cash-position-for-q3-2024 2024-11-13T21:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-13T21:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/genfit-announces-corporate-updates-and-upcoming-participation-at-the-liver-meeting-r-2024 2024-11-13T21:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/nurexone-biologic-secures-ema-orphan-status-for-exopten-in-globenewswire 2024-11-13T21:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T21:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-13T21:13:55+00:00 weekly 0.7 https://trial.medpath.com/news/structure-therapeutics-announces-first-patients-dosed-in-phase-2b-access-clinical-study 2024-11-13T21:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/genfit-announces-corporate-updates-and-upcoming-participation-at-the-liver-meeting-r-2024 2024-11-13T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharma-to-present-key-fibromyalgia-drug-data-awaits-fda-decision-on-fast 2024-11-13T21:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T21:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/structure-therapeutics-launches-phase-2b-obesity-drug-trial-expands-testing-to-higher-doses 2024-11-13T21:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/taysha-gene-reports-strong-safety-data-fda-approval-for-tsha-102-trials-stock-titan 2024-11-13T21:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-13T21:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/how-a-gene-agnostic-approach-opens-doors-to-new-therapeutics-ophthalmology-times-europe 2024-11-13T21:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/syros-s-hopes-dashed-as-tamibarotene-flunks-phase-iii-mds-trial-citeline 2024-11-13T21:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/novabone-receives-fda-clearance-for-expanded-indications-of-putty-in-interbody-fusion 2024-11-13T20:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-de-novo-clearance-to-stone-clear-device-urology-times 2024-11-13T20:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-reports-third-quarter-2024-financial-information-yahoo-finance 2024-11-13T20:35:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmission-of-pz-cel-gene-therapy-bla-for-epidermolysis-bullosa 2024-11-13T20:33:03+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv 2024-11-13T20:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/ethics-board-approval-granted-for-lexaria-s-12-week-phase-1b-dehydratech-glp-1-study 2024-11-13T20:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/agenus-top-brass-sued-over-fda-response-to-cancer-drug-trial-bloomberg-law-news 2024-11-13T20:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/wint-patient-enrollment-in-seismic-c-trial-starts-patent-position-expands 2024-11-13T20:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/remdesivir-becomes-the-first-drug-for-covid-19-recommended-for-use-in-the-eu-telegrafi 2024-11-13T19:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-ceo-wants-to-focus-on-development-amid-rebuilding-it-really-changes-lundbeck-s-profile 2024-11-13T19:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/cellid-finishes-phase-3-dosing-of-omicron-targeted-covid-19-vaccine-kbr 2024-11-13T19:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-from-the-2024-world-conference-on-lung-cancer-the-asco-post 2024-11-13T19:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/trex-bio-raises-84m-to-compete-in-crowded-immune-drug-field-biopharma-dive 2024-11-13T19:00:38+00:00 weekly 0.7 https://trial.medpath.com/news/preventing-rejection-in-pancreatic-islet-transplant-uchicago-medicine 2024-11-13T18:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-companion-diagnostic-assay-the-asco-post 2024-11-13T18:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/atsena-therapeutics-and-nippon-shinyaku-enter-exclusive-license-agreement-for-atsn-101 2024-11-13T18:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-seek-us-fda-s-accelerated-approval-for-datopotamab-pharmabiz 2024-11-13T18:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-merck-s-koselugo-shows-promise-in-adults-with-neurofibromatosis-type-1 2024-11-13T18:24:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-med-el-cochlear-implant-indications-the-hearing-review 2024-11-13T18:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/ars-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-13T17:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/msd-and-astrazeneca-report-positive-topline-data-from-koselugo-trial-for-nf1 2024-11-13T17:53:05+00:00 weekly 0.7 https://trial.medpath.com/news/kadimastem-nls-merge-to-advance-als-therapy-astrorx-other-drugs-als-news-today 2024-11-13T17:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/atai-posts-26m-loss-but-progresses-on-psychedelic-clinical-trials-green-market-report 2024-11-13T17:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/can-canada-s-psychedelic-drug-developers-shake-off-the-sector-s-bad-trip 2024-11-13T17:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/x4-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T17:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-outpatient-cardiac-telemetry-for-smartcardia-ecg-patch-massdevice 2024-11-13T17:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-on-pst-611-from-pulsesight-therapeutics-sas-shared-at-ever-congress-2024 2024-11-13T17:23:28+00:00 weekly 0.7 https://trial.medpath.com/news/koselugo-demonstrates-clinically-meaningful-improvement-in-adults-with-symptomatic 2024-11-13T17:17:50+00:00 weekly 0.7 https://trial.medpath.com/news/kezar-struck-again-with-second-fda-hold-clinical-trials-arena 2024-11-13T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-s-stock-sinks-by-25-despite-aml-trial-meeting-primary-endpoint 2024-11-13T17:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/momelotinib-wins-canadian-approval-for-myelofibrosis-with-anemia-onclive 2024-11-13T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-receives-fda-clearance-for-head-only-signa-magnus-3-0t-mri-system 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/sonomotion-announces-fda-de-novo-clearance-for-its-stone-cleartm-device 2024-11-13T17:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-significantly-improves-responses-vs-placebo-in-tgct-cancer-network 2024-11-13T17:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-reports-third-quarter-2024-financial-information-stock-titan 2024-11-13T17:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-and-limmatech-announce-first-vaccination-in-phase-2b-human-challenge-study 2024-11-13T16:48:43+00:00 weekly 0.7 https://trial.medpath.com/news/lenacapavir-for-prep-demonstrates-strong-efficacy-adherence-in-phase-3-trial 2024-11-13T16:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-reports-third-quarter-2024-financial-information-globenewswire 2024-11-13T16:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-full-approval-of-ocaliva-as-second-line-pbc-treatment-liver-disease-news 2024-11-13T16:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-and-mtm-vision-join-forces-to-combat-vision-loss-from-diabetes 2024-11-13T16:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/livanova-hits-goals-in-sleep-apnea-implant-trial-plans-fda-filing-medtech-dive 2024-11-13T16:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/chlorhexidine-alcohol-compared-with-povidone-iodine-alcohol-skin-antisepsis-protocols-in 2024-11-13T16:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-shares-sink-on-obesity-drug-concerns-astrazeneca-to-spend-3-5b-on-manufacturing 2024-11-13T16:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/improving-atopic-dermatitis-treatment-for-adolescents-feinberg-news-center 2024-11-13T16:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-sanofi-s-dupixent-approval-signals-major-treatment-breakthrough-for-smokers 2024-11-13T16:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-may-help-curb-alcohol-addiction-study-suggests 2024-11-13T16:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-magnetic-stimulation-slows-alzheimer-s-progression-in-phase-ii-study 2024-11-13T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-receives-approval-for-phase-iii-dfi-trial-in-indonesia 2024-11-13T16:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-fights-lethal-childhood-brain-cancer-in-stanford-medicine-trial-news-center 2024-11-13T16:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/intercept-loses-ocaliva-fda-full-approval-bid-in-rare-liver-disease 2024-11-13T15:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/non-cystic-fibrosis-bronchiectasis-pipeline-insight-over-globenewswire 2024-11-13T15:38:07+00:00 weekly 0.7 https://trial.medpath.com/news/minoryx-ceo-marc-martinell-discusses-a-new-small-molecule-therapeutic-for-ald 2024-11-13T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/komet-phase-iii-trial-of-koselugo-shows-statistically-significant-and-clinically-meaningful 2024-11-13T15:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial-evaluating-potential 2024-11-13T15:21:01+00:00 weekly 0.7 https://trial.medpath.com/news/trace-neuroscience-launches-with-101m-and-a-potential-genomic-als-target 2024-11-13T15:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/asha-therapeutics-awarded-barnett-drug-development-grant-by-the-als-association-to 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early 2024-11-13T15:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-in-nsclc-the-power-of-molecular-testing-cancer-network 2024-11-13T15:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-gsk-s-ojjaara-for-myelofibrosis-in-anaemia-patients 2024-11-13T15:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/induction-of-cure-in-early-arthritis-i-cea-study-protocol-for-an-investigator-initiated-trials 2024-11-13T14:38:46+00:00 weekly 0.7 https://trial.medpath.com/news/asha-therapeutics-secures-als-grant-for-breakthrough-sarm1-drug-development 2024-11-13T14:36:43+00:00 weekly 0.7 https://trial.medpath.com/news/lexaria-s-dehydratech-diabetes-study-advances-fda-track-phase-1b-trial-gets-key-approval 2024-11-13T14:36:41+00:00 weekly 0.7 https://trial.medpath.com/news/rejuvenating-lung-stem-cells-for-idiopathic-pulmonary-fibrosis-drug-discovery-news 2024-11-13T14:24:08+00:00 weekly 0.7 https://trial.medpath.com/news/atai-life-sciences-advances-therapeutic-pipeline-in-q3-with-fda-approval-of-vls-01 2024-11-13T14:22:30+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-hits-major-milestone-208-patients-enrolled-in-phase-2-alzheimer-s-trial 2024-11-13T14:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-morningstar 2024-11-13T14:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/helix-debuts-novel-precision-effectiveness-model-that-predicts-12-month-weight-loss 2024-11-13T14:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-announces-final-enrollment-of-208-patients-globenewswire 2024-11-13T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/gemvax-kael-announces-results-from-phase-2a-clinical-trial-for-psp-aftd 2024-11-13T14:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-gets-fda-approval-for-head-only-mri-scanner-morningstar 2024-11-13T13:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/intelligent-bio-solutions-hits-major-breakthrough-in-drug-detection-study-fda-filing-next 2024-11-13T13:38:22+00:00 weekly 0.7 https://trial.medpath.com/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial-yahoo-finance 2024-11-13T13:32:41+00:00 weekly 0.7 https://trial.medpath.com/news/ibi354-shows-efficacy-and-safety-in-her2-and-her2-low-advanced-breast-cancer 2024-11-13T13:27:58+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T13:24:18+00:00 weekly 0.7 https://trial.medpath.com/news/biorestorative-therapies-inc-reports-positive-preliminary-phase-2-brtx-100-clinical-data 2024-11-13T13:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-inc-added-to-prism-emerging-biotech-index-globenewswire 2024-11-13T13:15:50+00:00 weekly 0.7 https://trial.medpath.com/news/inovio-s-ino-3107-shows-breakthrough-immune-response-in-rrp-treatment-trial 2024-11-13T13:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/moonlake-immunotherapeutics-starts-phase-3-izar-program-of-globenewswire 2024-11-13T13:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/med-el-corporation-announces-fda-approval-of-expanded-candidacy-indications-and 2024-11-13T13:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/enveda-announces-first-candidate-discovered-from-nature-using-ai-advances-to-clinical-trials 2024-11-13T13:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/smartcardia-receives-fda-clearance-for-outpatient-cardiac-telemetry-for-its-7-lead-ecg 2024-11-13T13:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/shilpa-medicare-s-acceptance-by-usfda-of-nda-filed-by-its-cdmo-partner-unicycive-for 2024-11-13T12:55:44+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/mural-oncology-announces-third-quarter-2024-financial-results-and-provides-update-on 2024-11-13T12:41:11+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for 2024-11-13T12:40:49+00:00 weekly 0.7 https://trial.medpath.com/news/jeremie-calais-md-highlights-study-of-psma-pet-vs-bone-scan-in-metastatic-prostate-cancer 2024-11-13T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-nipocalimab-granted-fda-breakthrough-designation-for-sjogren-s-disease-pmlive 2024-11-13T12:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13T12:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-13T12:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/leap-therapeutics-reports-third-quarter-2024-financial-results-stock-titan 2024-11-13T12:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-commences-phase-iii-trial-of-bexicaserin-for-dees-seizure-treatment 2024-11-13T12:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/syros-stock-craters-after-lead-cancer-therapy-flops-in-phase-iii-trial 2024-11-13T11:53:09+00:00 weekly 0.7 https://trial.medpath.com/news/x4-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-13T11:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-announces-publication-of-data-from-phase-1-1b-clinical-trial-of-imu-856-pr-newswire 2024-11-13T11:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/gyre-therapeutics-reports-third-quarter-2024-and-year-to-date-financial-results-and 2024-11-13T11:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/gyre-therapeutics-reports-third-quarter-2024-and-globenewswire 2024-11-13T11:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-biospace 2024-11-13T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-seek-approval-for-first-drug-to-treat-high-risk-smoldering-myeloma-pharmafile 2024-11-13T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-13T10:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-provides-statement-on-maritide-phase-1-data 2024-11-13T10:20:23+00:00 weekly 0.7 https://trial.medpath.com/news/immuneonco-advances-cancer-drug-trials-with-promising-results-tipranks-com 2024-11-13T10:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/menin-suits-syndax-s-revumenib-phase-ii-win-in-aml-measured-bioworld 2024-11-13T09:57:58+00:00 weekly 0.7 https://trial.medpath.com/news/mediprint-ophthalmics-reveals-positive-results-from-phase-2b-study-of-ll-bmt1-contact-lens 2024-11-13T09:55:41+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T09:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/curateq-biologics-gains-ema-gmp-certification-for-biosimilars-facility 2024-11-13T09:33:32+00:00 weekly 0.7 https://trial.medpath.com/news/astrazenecas-contribution-to-the-breast-cancer-market-precedence-research 2024-11-13T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/topical-drug-combos-may-be-beneficial-for-cipn-oncology-nursing-news 2024-11-13T09:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb310-precision-microbiome-therapy-for-ulcerative-colitis 2024-11-13T09:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/global-pharma-s-investment-in-korean-clinical-research-grew-7-in-2023-krpia-kbr 2024-11-13T08:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-to 2024-11-13T08:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-clears-investigational-new-drug-application-for-crispr-cas13-rna-editing-therapy 2024-11-13T08:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drug-pembrolizumab-improves-outcomes-for-patients-with-soft-tissue-sarcoma 2024-11-13T08:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/lyophilization-drives-15-annual-growth-in-novel-drug-approvals-reshaping-pharmaceutical-manufacturing 2024-11-13T08:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/glucose-responsive-insulin-for-diabetes-nature-biotechnology 2024-11-13T07:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-significantly-improved-outcomes-for-patients-with-tenosynovial-giant-cell 2024-11-13T06:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/myriad-genetics-expands-prenatal-testing-access-with-retail-launch-of-sneakpeek-early-fetal-sex-test 2024-11-13T06:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-13T05:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-13T05:38:16+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-doses-first-patient-in-canada-for-phase-ii-trial-of-lsalt-peptide-to-treat 2024-11-13T05:31:11+00:00 weekly 0.7 https://trial.medpath.com/news/regulator-defends-new-drug-approval-fee-hike-plans-faster-review-process-kbr 2024-11-13T05:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-13T04:59:07+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-shows-promise-in-aml-trial-phase-2-results-investing-com 2024-11-13T04:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-resumes-phase-3-vaccine-trials-after-fda-hold-tipranks-com 2024-11-13T04:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/spinal-cord-injury-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-11-13T04:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-tenosynovial-giant-cell-tumors-clinical-trials-highlighted-for-2024 2024-11-13T04:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-regeneron-pharmaceuticals-dupixent-approval-marks-a-significant-shift-pr-newswire 2024-11-13T04:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-11-13T04:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-traumatic-brain-injury-clinical-trials-highlighted-for-2024 2024-11-13T04:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-anti-espionage-law-threatens-global-pharmaceutical-supply-chain-security 2024-11-13T04:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-updates 2024-11-13T03:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-pharma-s-partner-centessa-initiates-phase-2-trial-with-orx750-a-novel-orexin 2024-11-13T03:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-formulation 2024-11-13T03:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/safety-reporting-in-trials-on-glaucoma-interventions-registered-in-clinicaltrials-gov-and 2024-11-13T03:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/regulator-and-funder-fda-s-orphan-products-grants-program-awards-significant-funding 2024-11-13T02:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous-co-pr-newswire 2024-11-13T02:50:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kebilidi-eladocagene-exuparvovec-tneq-gene-therapy-for-the-treatment-of-aadc-deficiency 2024-11-13T02:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-chemotherapy-combo-boosts-pfs-in-chl-poised-for-standard-use 2024-11-13T02:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-legend-biotech-sees-robust-growth-in-carvykti-sales-investing-com 2024-11-13T01:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/elraglusib-gains-fda-rare-pediatric-disease-designation-in-ewing-sarcoma 2024-11-13T01:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/a-scrap-of-data-on-amgen-s-obesity-drug-maritide-wipes-out-12b-in-market-value-stat-news 2024-11-13T01:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-mondaq 2024-11-13T00:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-explores-sale-of-hospital-drugs-unit-amid-strategic-restructuring 2024-11-13T00:36:50+00:00 weekly 0.7 https://trial.medpath.com/news/lung-cancer-takes-big-beating-from-tiny-nano-particles-synbiobeta 2024-11-13T00:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-drug-eluting-bead-transarterial-chemoembolization-combined-with-apatinib-nature 2024-11-13T00:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-pharma-q3-new-patent-win-trial-progress-despite-cash-decline 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash 2024-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-12T23:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-revolution-in-antibody-therapy-q-a-with-randy-noelle-phd-geisel-news 2024-11-12T23:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-clinical-trial-of-descartes-08-for-mg-may-start-in-2025-myasthenia-gravis-news 2024-11-12T23:40:13+00:00 weekly 0.7 https://trial.medpath.com/news/huidagene-therapeutics-ind-application-for-hg202-for-the-treatment-of-namd-cleared-by-fda 2024-11-12T23:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-validation-and-real-world-impact-of-precivityad2-test-for-alzheimer-diagnosis 2024-11-12T23:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-agreement-with-the-us-national-cancer-institute-to 2024-11-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/eupraxia-s-eoe-drug-shows-breakthrough-results-complete-remission-in-latest-trial-data 2024-11-12T23:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sets-pfuda-date-accepts-bla-submission-for-pz-cel-in-epidermolysis-bullosa 2024-11-12T23:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/fox-chase-cancer-center-s-dr-vanessa-wookey-presents-rectal-cancer-research-at-24th 2024-11-12T23:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T23:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-clinical-trials-face-logistical-challenges-experts-to-address-solutions-at-brussels-conference 2024-11-12T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-new-bla-for-dato-dxd-in-pretreated-egfr-advanced-nsclc-onclive 2024-11-12T22:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/selumetinib-boosts-orr-in-nf1-with-inoperable-plexiform-neurofibroma-onclive 2024-11-12T22:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-full-approval-of-liver-disease-drug-medpage-today 2024-11-12T22:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/aura-biosciences-inc-sec-10-q-report-tradingview 2024-11-12T22:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates 2024-11-12T22:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/3-things-to-know-about-cobenfy-the-new-schizophrenia-drug-yale-medicine 2024-11-12T22:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-combination-improves-outcomes-for-small-cell-bladder-and-prostate-cancer-patients 2024-11-12T22:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-cap-002-gains-fda-orphan-drug-designation-for-stxbp1-developmental 2024-11-12T22:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-12T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-blood-test-detects-early-lung-damage-in-cancer-patients-on-targeted-therapy 2024-11-12T21:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/collaboration-to-support-phase-3-secure-trial-of-67cu-sar-bispsma-urology-times 2024-11-12T21:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-advances-clinical-trials-in-q3-ahead-of-data-rich-2025-nasdaq-lsta 2024-11-12T21:32:47+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-12T21:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/oncocyte-reports-commercial-launch-progress-on-track-to-sign-20-transplant-centers-by 2024-11-12T21:29:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ai-powered-breast-cancer-detection-tech-from-icad-massdevice 2024-11-12T21:22:06+00:00 weekly 0.7 https://trial.medpath.com/news/jenavalve-to-begin-trilogy-heart-valve-trial-massdevice 2024-11-12T21:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-reports-third-quarter-2024-financial-globenewswire 2024-11-12T21:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/perspective-therapeutics-reports-267-8m-cash-position-advances-cancer-drug-trials 2024-11-12T21:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/artiva-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights 2024-11-12T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights 2024-11-12T21:17:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-renewal-for-canine-chemotherapy-induced-diarrhea-treatment 2024-11-12T21:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/automatic-segmentation-based-multi-modal-radiomics-analysis-of-us-and-mri-for-predicting 2024-11-12T21:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-reports-third-quarter-2024-globenewswire 2024-11-12T21:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-fiscal-3q-2024-results 2024-11-12T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-provides-business-update-and-reports-third-quarter-2024-stock-titan 2024-11-12T21:06:52+00:00 weekly 0.7 https://trial.medpath.com/news/inflammatix-begins-trial-evaluating-mrna-test-for-patient-infection-status 2024-11-12T21:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-announces-third-quarter-2024-financial-results-and-business-developments 2024-11-12T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucl-spinout-autolus-gains-us-approval-for-cancer-therapy 2024-11-12T20:58:54+00:00 weekly 0.7 https://trial.medpath.com/news/dyne-therapeutics-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-12T20:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-11-12T20:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2024-11-12T20:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-announces-koselugo-met-primary-endpoing-in-komet-phase-iii-trial 2024-11-12T20:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-plans-pivotal-trial-for-ai-based-ipf-candidate 2024-11-12T20:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-suggests-weight-loss-drugs-like-ozempic-could-help-with-knee-pain-here-s-why 2024-11-12T19:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-positive-pivotal-topline-results-from-relapsed-or-refractory-mnpm1-aml-cohort-in-augment-101-trial-of-revumenib 2024-11-12T19:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/drug-for-infertility-puberty-disorders-hot-flashes-soon-us-scientist-times-of-india 2024-11-12T19:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-s-pimicotinib-meets-endpoints-in-phase-iii-bioworld 2024-11-12T19:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio 2024-11-12T19:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-sankyo-submit-biologics-license-application-of-datopotamab 2024-11-12T18:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-wins-fda-ide-for-ottava-surgical-robot-massdevice 2024-11-12T18:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-eurekalert 2024-11-12T18:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-announced-positive-phase-1-results-for-its-oral-glp-yahoo-finance 2024-11-12T18:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/prokidney-reports-third-quarter-2024-financial-results-globenewswire 2024-11-12T18:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-autolus-aucatzyl-for-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-12T18:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-ever-randomized-clinical-trial-uses-telehealth-for-suicide-prevention-ohio-state-medical-center 2024-11-12T18:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-holding-corp-sec-10-q-report-tradingview 2024-11-12T18:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-11-12T18:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-announces-fda-rare-pediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma 2024-11-12T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-ocaliva-full-approval-in-primary-biliary-cholangitis-safety-data-still-in-play 2024-11-12T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/indaptus-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T18:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/naim-alkhouri-md-first-real-world-data-for-resmetirom-use-in-clinical-practice-hcplive 2024-11-12T18:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-for-npm1-mutant-aml-succeeds-in-pivotal-trial-targeted-oncology 2024-11-12T18:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/key-clinical-compound-updates-from-october-2024 2024-11-12T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-cases-in-bluebird-s-gene-therapy-trials-nature-biotechnology 2024-11-12T17:41:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ai-procured-ism001-055-demonstrates-great-promise-for-treatment-of-ipf 2024-11-12T17:36:25+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-reports-results-from-trial-of-cvn293-for-neurodegenerative-conditions 2024-11-12T17:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-combined-covid-19-influenza-vaccine-trials 2024-11-12T17:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-reports-third-quarter-2024-globenewswire 2024-11-12T17:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-s-pimicotinib-hits-primary-endpoint-in-phase-3-tgct-trial 2024-11-12T17:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/eu-crunch-time-for-kizfizo-sipavibart-coacillium-eight-other-products 2024-11-12T17:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/qnrx-international-sites-participating-in-qrx003-ns-study-zacks-small-cap-research 2024-11-12T17:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division-abc-news 2024-11-12T17:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-ottava-surgical-robot-to-begin-clinical-trial-after-fda-nod-medtech-dive 2024-11-12T17:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/pimicotinib-meets-orr-end-point-in-tenosynovial-giant-cell-tumor-onclive 2024-11-12T17:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/a-framework-for-n-of-1-trials-of-individualized-gene-targeted-therapies-for-genetic-diseases 2024-11-12T17:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-hits-a-setback-in-the-clinic-days-after-fundraise-biopharma-dive 2024-11-12T17:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine 2024-11-12T17:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/entinostat-in-combination-with-nivolumab-in-metastatic-pancreatic-ductal-adenocarcinoma 2024-11-12T17:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/uf-health-study-to-assess-pharmacogenetic-testing-in-the-er 2024-11-12T17:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/immuno-cure-biotech-presents-promising-results-on-phase-i-clinical-trial-of-a-therapeutic 2024-11-12T17:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/casting-a-wide-net-when-is-the-optimal-time-for-177lu-dotatate-treatment 2024-11-12T17:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-new-bla-for-dato-dxd-in-advanced-egfr-nsclc-cancer-network 2024-11-12T17:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-resubmission-for-epidermolysis-bullosa-gene-therapy-drug-topics 2024-11-12T16:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-investors-including-third-rock-pump-100m-into-a-startup-s-genetic-medicine-for-als 2024-11-12T16:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-pfa-trial-in-new-patient-group-after-pausing-enrollment 2024-11-12T16:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-nipocalimab-for-sjogren-s-disease-healio 2024-11-12T16:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-for-donidalorsen-healio 2024-11-12T16:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/dmts-are-major-clinical-research-focus-for-parkinson-s-disease-analysis-shows 2024-11-12T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-daiichi-revise-approval-plans-for-enhertu-successor-biopharma-dive 2024-11-12T16:26:24+00:00 weekly 0.7 https://trial.medpath.com/news/sareum-holdings-edison-vox-markets 2024-11-12T16:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/formation-bio-collaborates-with-openai-and-sanofi-to-introduce-muse-marketscreener 2024-11-12T16:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/one-genomic-test-can-diagnose-nearly-any-infection-uc-san-francisco 2024-11-12T16:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/peta-the-oncostory-that-started-when-he-was-four-months-old-the-university-hospital-brno 2024-11-12T15:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-bioforum-bolster-decade-long-relationship-to-advance-clinical-data-and 2024-11-12T15:57:18+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-fda-green-light-for-robotic-system-trial-marketscreener 2024-11-12T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/nevro-wins-ce-mark-for-hfx-iq-spinal-cord-stim-for-pain-relief-massdevice 2024-11-12T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/magstim-earns-fda-clearance-for-transcranial-magnetic-stimulation-that-treats-depression-ocd 2024-11-12T15:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-removes-clinical-hold-on-novavax-s-covid-19-influenza-combo-vaccine 2024-11-12T15:37:30+00:00 weekly 0.7 https://trial.medpath.com/news/merck-drug-for-rare-tumour-hits-phase-3-target-pharmaphorum 2024-11-12T15:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/how-pfizer-used-wearables-to-tap-into-the-promise-of-an-experimental-drug-stat-news 2024-11-12T15:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-triplet-therapy-for-advanced-stage-pik3ca-mutant-hr-breast-cancer-improves-outcomes 2024-11-12T15:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/buy-sell-or-hold-bmy-stock-forbes 2024-11-12T15:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-inc-sec-10-q-report-tradingview 2024-11-12T15:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/prominent-usc-scientist-goes-on-leave-amid-research-misconduct-allegations-national 2024-11-12T15:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/antelope-surgical-solutions-achieves-commercial-investigational-new-drug-ind-approval 2024-11-12T15:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/zolbetuximab-plus-chemotherapy-offers-survival-benefits-in-treatment-naive-her2-onclive 2024-11-12T15:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-doses-first-subject-in-trial-of-acute-kidney-injury-treatment 2024-11-12T15:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-scanning-of-genetic-variants-with-base-and-prime-editing-nature-biotechnology 2024-11-12T15:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/seattle-children-s-now-enrolling-participants-for-first-u-s-car-t-cell-clinical-trial-for 2024-11-12T14:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-final-call-on-alzheimer-s-drug-leqembi-imminent-citeline 2024-11-12T14:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct 2024-11-12T14:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-of-work-an-atypical-schizophrenia-drug-is-approved 2024-11-12T14:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/refined-definition-of-platinum-resistance-novel-adcs-could-brind-more-changes-to-onclive 2024-11-12T14:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/komet-phase-iii-trial-met-primary-endpoint-shares-magazine 2024-11-12T14:22:23+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-givlaari-r-swissmedic 2024-11-12T14:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-crl-to-obeticholic-acid-ocaliva-denies-full-approval-for-pbc-hcplive 2024-11-12T14:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-therapeutics-highlights-presentation-at-european-yahoo-finance 2024-11-12T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-disappointing-schizophrenia-drug-trial-bodes-well-for-rival-bristol-myers-analysts-say 2024-11-12T14:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-s-tecarfarin-shows-promise-for-lvad-patients-in-key-medical-congress-data 2024-11-12T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/woolsey-pharmaceuticals-completes-patient-recruitment-for-high-dose-cohort-of-als-study 2024-11-12T14:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/cadrenal-therapeutics-highlights-presentation-at-european-placera 2024-11-12T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-initiates-phase-3-deep-ocean-study-evaluating-bexicaserin 2024-11-12T13:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-unit-gets-ema-nod-for-biosimilar-facility-the-week 2024-11-12T13:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/caliway-announced-ema-orphan-drug-designation-granted-to-cbl-514-for-dercum-s 2024-11-12T13:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-globenewswire 2024-11-12T13:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T13:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/acuitive-technologies-receives-fda-510-k-clearance-for-globenewswire 2024-11-12T13:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/icad-s-profound-detection-version-4-0-gains-fda-clearance-globenewswire 2024-11-12T13:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/savara-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T13:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-submits-eu-and-us-applications-for-subcutaneous-darzalex-in-smouldering-multiple-myeloma 2024-11-12T13:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-the-enrollment-and-dosing-of-the-first-10-patient-in-the-randomized 2024-11-12T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-stock-plummets-over-12-after-schizophrenia-drug-flops-in-phase-ii-trials 2024-11-12T13:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-breakthrough-fda-fast-track-cancer-drug-advances-to-pivotal-phase-3-trial 2024-11-12T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-s-allocetra-advances-phase-ii-trial-launches-for-knee-osteoarthritis-treatment 2024-11-12T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-receives-institutional-review-board-approval-for-miracle-phase-3-pivotal-trial 2024-11-12T13:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-third-quarter-2024-financial-results-and-operational-highlights 2024-11-12T13:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T13:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral 2024-11-12T12:52:09+00:00 weekly 0.7 https://trial.medpath.com/news/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-pr-newswire 2024-11-12T12:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-reports-third-quarter-2024-financial-globenewswire 2024-11-12T12:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-announces-fda-clinical-hold-lift-on-phase-3-covid-19-flu-vaccine-study-pmlive 2024-11-12T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-manufacturing-agreement-with-sterling-for-gnx102-adc-clinical-trial 2024-11-12T12:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-reports-third-quarter-2024-financial-results-and-business-update 2024-11-12T12:34:20+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-s-ibd-drug-shows-breakthrough-90-day-half-life-in-phase-1-trial-4x-better-than-standard 2024-11-12T12:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-r-announces-fda-acceptance-of-bla-globenewswire 2024-11-12T12:33:54+00:00 weekly 0.7